格拉普兰特

Description

Grapiprant · CAS 415903-37-6 · C26H29N5O3S. UNII J9F5ZPH7NB. LogP: 4.56.

Identification

CAS Registry Number	415903-37-6
PubChem CID	11677589
Molecular formula	C26H29N5O3S
IUPAC name	1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea
UNII (FDA)	J9F5ZPH7NB

Computed Descriptors

Molecular Weight	491.6
XLogP3	4.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	491.19911098
Monoisotopic Mass	491.19911098
Topological Polar Surface Area	114
Heavy Atom Count	35
Formal Charge	0

Physical & Chemical Properties

LogP	4.56

Physical description & handling notes

• >136 ºC (Grapiprant hydrochloride)
• Insoluble
• Preclinical studies have shown that grapiprant is very effective to reduce acute and chronic pain and inflammation. The effect of grapiprant seems to be dose-dependent and it is comparable to the effect of rofecoxib and piroxicam. The effects of grapiprant have been reported to be effective in the relief from arthritic pain in canine patients.

GHS Hazard Classification

Reported hazard statements	H302 (100%)

Documented Uses

• Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
• QM01 - Antiinflammatory and antirheumatic products
• QM01A - Antiinflammatory and antirheumatic products, non-steroids
• QM01AX - Other antiinflammatory and antirheumatic agents, non-steroids
• Studies in animals (horse) have shown the presence of a concentration >0.005 ng/ml in serum 72 hours after initial administration of a dose of 2 mg/kg. It is rapidly absorbed and the reported Cmax in this reports was 31.9 ng/ml in a Tmax of 1.5 hours and AUC of 2000 ng.hr/ml. In the case of bioavailability, grapiprant presents a mean bioavailability of 39%. The bioavailability, time for peak concentration and maximal concentration has been reported to be significantly reduced after food.
• Following an oral dose, the majority of the dose an within the first 72 hours. Studies in animals (horse) have shown the presence of a concentration >0.005 ng/ml in urine 96 hours after initial administration of a dose of 2 mg/kg. From the excreted dose, 55%, 15% and 19% of the administered dose is excreted in bile, urine, and feces respectively.

Synonyms

Grapiprant; 415903-37-6; CJ-023423; CJ 023423; CJ-023,423; AAT-007; MR-10A7; CJ-023; MR10A7; RQ-00000007; J9F5ZPH7NB; 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea; DTXSID60194419; 1-(2-(4-(2-ethyl-4,6-dimethylimidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)-3-(4-methylphenyl)sulfonylurea; grapiprantum; Galliprant

Frequently Asked Questions

What are the CAS number and molecular formula of Grapiprant?

CAS 415903-37-6; molecular formula C26H29N5O3S; molecular weight — g/mol.

What other names is Grapiprant known by?

Grapiprant, 415903-37-6, CJ-023423, CJ 023423, CJ-023,423, AAT-007.

Is Grapiprant classified as hazardous?

Hazard statements reported: H302.

What are the key physical properties of Grapiprant?

LogP: 4.56.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.